Skip to main content
. 2023 Sep 18;23:873. doi: 10.1186/s12885-023-11389-x

Table 6.

Adverse events in the Atez/Bev group

Adverse Event All Events CTCAE Grade
1 2 3
Hypertension 15 (19.5%) 9 (11.7%) 4 (5.2%) 2 (2.6%)
Proteinuria 7 (9.1%) 3 (3.9%) 3 (3.9%) 1 (1.3%)
Fatigue 5 (6.5%) 4 (5.2%) 1 (1.3%) 0 (0%)
Diarrhea 3 (3.9%) 2 (2.6%) 1 (1.3%) 0 (0%)
Pneumonitis 1 (1.3%) 0 (0%) 1 (1.3%) 0 (0%)

CTCAE Common Terminology Criteria for Adverse Events, Atez/Bev Atezolizumab/bevacizumab